Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
250 Results for "
complex II
" in MedChemExpress (MCE) Product Catalog:
Products (250)
250 Results for "complex II" in MCE Product Catalog:
Cat. No.: HY-P80984
Synonyms: CK-5; CK5; Cytokeratin-5; Cytokeratin5; DDD; DDD1; EBS2; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types; K2C5_HUMAN; K5; keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types); Keratin 5; Keratin ; keratin complex 2, basic, gene 5; keratin, type II cytoskeletal 5 ; Keratin-5; Keratin5; KRT 5; Krt5; KRT5A; type II cytoskeletal 5 ; Type-II keratin Kb5;
Cat. No.: HY-P812030A
Synonyms: MED27; Mediator complex Subunit 27; CRSP34; TRAP37; CRSP8; MED3; Cofactor Required For Sp1 Transcriptional Activation, Subunit 8, 34kDa; Mediator Of RNA Polymerase II Transcription Subunit 27; Transcriptional Coactivator CRSP34; P37 TRAP/SMCC/PC2 Subunit; CRSP complex Subunit 8; Cofactor Required For Sp1 Transcriptional Activation Subunit 8; Epididymis Secretory Sperm Binding Protein; NEDSCAC; CRAP34
Cat. No.: HY-L018
458 compounds
The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc.
MCE designs a unique collection of 458 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.
Cat. No.: HY-P702941
Purity: ≥ 80%, as determined by reducing SDS-PAGE.
Synonyms: CDK8; Cell Division Protein Kinase 8; Cyclin Dependent Kinase 8; Mediator complex Subunit CDK8; Cyclin-Dependent Kinase 8; Protein Kinase K35; K35; CDK8 Protein Kinase; Mediator Of RNA Polymerase II Transcription Subunit CDK8; IDDHBA
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P703557
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CDK8; Cell Division Protein Kinase 8; Cyclin Dependent Kinase 8; Mediator complex Subunit CDK8; Cyclin-Dependent Kinase 8; Protein Kinase K35; K35; CDK8 Protein Kinase; Mediator Of RNA Polymerase II Transcription Subunit CDK8; IDDHBA
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P705018
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: FCGRT; Major Histocompatibility complex Class I-Like Fc Receptor; Fc Gamma Receptor And Transporter; Neonatal Crystallizable Fc Receptor FcRn Splice Variant 6; Neonatal Fc Receptor; Neonatal Crystallizable Fc Receptor FcRn Splice Variant 5; FcRn; Neonatal
Species:
Cynomolgus
Source:
HEK293
Cat. No.: HY-P705020
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: FCGRT; Major Histocompatibility complex Class I-Like Fc Receptor; Fc Gamma Receptor And Transporter; Neonatal Crystallizable Fc Receptor FcRn Splice Variant 6; Neonatal Fc Receptor; Neonatal Crystallizable Fc Receptor FcRn Splice Variant 5; FcRn; Neonatal
Species:
Rat
Source:
HEK293
Cat. No.: HY-P705300
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: FCGRT; Major Histocompatibility complex Class I-Like Fc Receptor; Fc Gamma Receptor And Transporter; Neonatal Crystallizable Fc Receptor FcRn Splice Variant 6; Neonatal Fc Receptor; Neonatal Crystallizable Fc Receptor FcRn Splice Variant 5; FcRn; Neonatal
Species:
Human
Source:
HEK293
Cat. No.: HY-119976R
CAS No.: 188425-85-6
Cat. No.: HY-183070
CXJ2080 is a selective PROTAC-based CDK7 degrader with a DC50 of 0.88 nM. CXJ2080 recruits VHL E3 ligase to induce ubiquitin-proteasome-dependent CDK7 degradation, disrupts the CDK7-cyclin H-MAT1 complex, suppresses CDK7-dependent phosphorylation of RNA polymerase II CTD Ser5, CDK1 Thr161, and CDK2 Thr160. CXJ2080 activates the p53-p21 axis, suppresses MYC-driven signaling, induces leukemia cell cycle arrest, apoptosis, and differentiation, reduces CD117 expression, spares platelets and normal PBMCs, maintains sustained CDK7 degradation post-washout. CXJ2080 can be used for the research of acute leukemia .
Cat. No.: HY-B2004R
CAS No.: 130000-40-7
Research Areas:
Thifluzamide (Standard) is the analytical standard of Thifluzamide. This product is intended for research and analytical applications. Thifluzamide is a fungicide that inhibits fungal respiration by blocking the ubiquinone-binding site in mitochondrial complex II. Thifluzamide exhibits significant activity against Basidiomycota pathogens (such as Rhizoctonia cerealis, Ustilago and Puccinia genera) and is commonly used in studies on wheat sharp eyespot. Thifluzamide displays a dual mechanism in regulating lipid metabolism: it reduces fatty acid synthase activity to inhibit endogenous fatty acid synthesis, and increases carnitine palmitoyltransferase-I activity to accelerate fatty acid β-oxidation, thereby reducing total cholesterol and triglyceride levels in the liver. Thifluzamide also induces hepatotoxicity in zebrafish models and carries a risk of developmental toxicity. Thifluzamide inhibition of Rhizoctonia cerealis may result in low to moderate levels of drug resistance, leading to the generation of stable drug-resistant mutants .
Cat. No.: HY-W663938
CAS No.: 400882-07-7
Research Areas:
Cyflumetofen is a non-systemic acylacetonitrile Acaricide. Cyflumetofen interferes with the Wnt/β-catenin signaling pathway, induces Apoptosis, and reduces the level of tight junction proteins. Cyflumetofen upregulates the expression of Pink1, Parkin and Lrrk2 genes associated with the pathogenesis of Parkinson's disease in zebrafish larvae. Cyflumetofen induces developmental toxicity and oxidative stress in zebrafish larvae, damages neurons, reduces motor activity, alters brain tissue structure, and disrupts blood-brain barrier structure. Cyflumetofen exhibits acaricidal activity against spider mites. Cyflumetofen can be used in studies related to Parkinson's disease and infestations by spider mites (Tetranychus urticae, Tetranychus kanzawai, Panonychus citri) .
Cat. No.: HY-W663938R
CAS No.: 400882-07-7
Cyflumetofen (Standard) is the analytical standard of Cyflumetofen (HY-W663938). This product is intended for research and analytical applications. Cyflumetofen is a non-systemic acylacetonitrile Acaricide. Cyflumetofen interferes with the Wnt/β-catenin signaling pathway, induces Apoptosis, and reduces the level of tight junction proteins. Cyflumetofen upregulates the expression of Pink1, Parkin and Lrrk2 genes associated with the pathogenesis of Parkinson's disease in zebrafish larvae. Cyflumetofen induces developmental toxicity and oxidative stress in zebrafish larvae, damages neurons, reduces motor activity, alters brain tissue structure, and disrupts blood-brain barrier structure. Cyflumetofen exhibits acaricidal activity against spider mites. Cyflumetofen can be used in studies related to Parkinson's disease and infestations by spider mites (Tetranychus urticae, Tetranychus kanzawai, Panonychus citri) .
Cat. No.: HY-P85907
Synonyms: 58 kDa cytokeratin; CK-5; CK5; Cytokeratin-5; Cytokeratin5; DDD; DDD1; EBS2; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types; K2C5_HUMAN; K5; keratin 5; epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types; Keratin 5; Keratin; keratin complex 2, basic, gene 5; keratin, type II cytoskeletal 5; Keratin-5; Keratin5; KRT 5; Krt5; KRT5A; type II cytoskeletal 5; Type-II keratin Kb5; CK 6A; CK 6B; CK 6C; CK 6D; CK 6E; CK-6B; CK-6C; CK-6E; Cytokeratin 6a; Cytokeratin 6B; Cytokeratin 6C; Cytokeratin 6D; Cytokeratin 6E; Cytokeratin-6B; Cytokeratin-6C; Cytokeratin-6E; K2C6C_HUMAN; K6a keratin; K6b keratin; K6C; K6c keratin; K6d keratin; K6e keratin; Keratin; Keratin K6h; Keratin type II cytoskeletal 6A; Keratin type II cytoskeletal 6B; Keratin type II cytoskeletal 6C; Keratin type II cytoskeletal 6D; Keratin type II cytoskeletal 6E; Keratin-6C; KRT6A; KRT6B; KRT6C; KRT6D; KRT6E; type II cytoskeletal 6C; Type-II keratin Kb12; 58 kDa Cytokeratin antibody; CK-5 antibody; CK5 antibody; Cytokeratin-5 antibody; Cytokeratin5 antibody; DDD antibody; DDD1 antibody; EBS2 antibody; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types antibody; K2C5_HUMAN antibody; K5 antibody; keratin 5; epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types; antibody; Keratin 5 antibody; Keratin antibody; keratin complex 2, basic, gene 5 antibody; keratin, type II cytoskeletal 5 antibody; Keratin-5 antibody; Keratin5 antibody; KRT 5 antibody; Krt5 antibody; KRT5A antibody; type II cytoskeletal 5 antibody; Type-II keratin Kb5 antibody
Cat. No.: HY-P85984
Synonyms: 58 kDa cytokeratin; CK-5; CK5; Cytokeratin-5; Cytokeratin5; DDD; DDD1; EBS2; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types; K2C5_HUMAN; K5; keratin 5; epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types; Keratin 5; Keratin; keratin complex 2, basic, gene 5; keratin, type II cytoskeletal 5; Keratin-5; Keratin5; KRT 5; Krt5; KRT5A; type II cytoskeletal 5; Type-II keratin Kb5; CK 6A; CK 6B; CK 6C; CK 6D; CK 6E; CK-6B; CK-6C; CK-6E; Cytokeratin 6a; Cytokeratin 6B; Cytokeratin 6C; Cytokeratin 6D; Cytokeratin 6E; Cytokeratin-6B; Cytokeratin-6C; Cytokeratin-6E; K2C6C_HUMAN; K6a keratin; K6b keratin; K6C; K6c keratin; K6d keratin; K6e keratin; Keratin; Keratin K6h; Keratin type II cytoskeletal 6A; Keratin type II cytoskeletal 6B; Keratin type II cytoskeletal 6C; Keratin type II cytoskeletal 6D; Keratin type II cytoskeletal 6E; Keratin-6C; KRT6A; KRT6B; KRT6C; KRT6D; KRT6E; type II cytoskeletal 6C; Type-II keratin Kb12; 58 kDa cytokeratin antibody; CK-5 antibody; CK5 antibody; Cytokeratin-5 antibody; Cytokeratin5 antibody; DDD antibody; DDD1 antibody; EBS2 antibody; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types antibody; K2C5_HUMAN antibody; K5 antibody; keratin 5; epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types; antibody; Keratin 5 antibody; Keratin antibody; keratin complex 2, basic, gene 5 antibody; keratin, type II cytoskeletal 5 antibody; Keratin-5 antibody; Keratin5 antibody; KRT 5 antibody; Krt5 antibody; KRT5A antibody; type II cytoskeletal 5 antibody; Type-II keratin Kb5 antibody
Cat. No.: HY-13323B
CAS No.: 2101314-20-7
Research Areas:
CX-5461 hydrochloride is a selective, orally active RNA polymerase I inhibitor. CX-5461 hydrochloride disrupts the formation of the SL1-rDNA complex, thereby blocking the transcription initiation of ribosomal RNA without altering the activity of RNA polymerase II, DNA replication, or protein translation processes. CX-5461 hydrochloride upregulates the expression of p21, MDM2, Sestrin1/2, and phosphorylated AMPKα, and reduces the level of phosphorylated Akt. CX-5461 hydrochloride induces G2/G2/M cell cycle arrest, Autophagy, Apoptosis, and cellular senescence, and activates CHK1, CHK2, and RPA. CX-5461 hydrochloride can be used in research related to osteosarcoma, cervical cancer, hematologic malignancies, high-grade serous ovarian cancer, and solid tumors .
Cat. No.: HY-160267
CAS No.: 950403-60-8
Target:
Research Areas:
iPAF1C is a inhibitor of the polymerase-associated factor 1 complex (PAF1C) with specific targeting to the PAF1 binding groove of CTR9 (a key subunit of PAF1C). iPAF1C disrupts PAF1C assembly by interfering with the PAF1-CTR9 interaction. iPAF1C selectively impairs BRD4-mediated recruitment of PAF1 to chromatin at hypoxia-responsive genes and inhibits RNA polymerase II (RNAPII) pause release. iPAF1C increases the population of HIV-1 NL4.3 Nef-IRES-GFP infected primary human CD4 +T cells in a dose-dependent manner. PAF1C can be used for the study of infection and diseases associated with abnormal hypoxic adaptation (e.g., cancers, neurological disorders) .
Cat. No.: HY-163944
CAS No.: 3081311-94-3
Research Areas:
LL-K12-18 is a CDK12 kinase inhibitor and a dual-site molecular glue. LL-K12-18 inhibits human CDK12 with an IC50 value of 283.9 nM, and selectively degrades cyclin K via the ubiquitin-proteasome system by stabilizing the CDK12-DDB1 complex. LL-K12-18 downregulates DNA damage response genes, reduces the phosphorylation level of CTD Ser2 in RNA polymerase II, and modulates biomarkers such as ATM, RAD51, γ-H2AX and cleaved PARP, thereby effectively inducing apoptosis and inhibiting proliferation of breast cancer cells. LL-K12-18 exhibits high target selectivity and serves as a research tool for studies on triple-negative breast cancer .
Cat. No.: HY-W018798
CAS No.: 4005-51-0
1,3,4-Thiadiazol-2-amine is a 1,3,4-thiadiazole antitumor agent with the potential to penetrate the blood-brain barrier. 1,3,4-Thiadiazol-2-amine can induce hyperuricemia, and this effect is blocked by Nicotinamide (HY-B0150). 1,3,4-Thiadiazol-2-amine supports the simultaneous administration of Allopurinol (HY-B0219), and their combined use prevents hyperuricemia without reducing antitumor activity.\n1,3,4-Thiadiazol-2-amine is a condensation precursor for the synthesis of antibacterial Schiff bases and their Co/Cu/Ni/Zn (II) complexes. 1,3,4-Thiadiazol-2-amine is used in research related to tumors and bacterial infections .
Cat. No.: HY-P99529
CAS No.: 1804910-11-9
Synonyms: BAX1810; TAK-752; SM101
Target:
Research Areas:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
